MED13 and glioblastoma: Importantly, the immunoblot analysis showed that treatment with Senexin A significantly stabilizes MED13 protein levels, and that this effect is maintained upon the combinatory treatment with MMS in HAP1 cells (Figure 5A and B), as well as HeLa adenocarcinoma and T98G glioblastoma cells (Supplementary Figure S5B–D).